AR099303A1 - Construcciones de aptámeros - Google Patents

Construcciones de aptámeros

Info

Publication number
AR099303A1
AR099303A1 ARP150100345A ARP150100345A AR099303A1 AR 099303 A1 AR099303 A1 AR 099303A1 AR P150100345 A ARP150100345 A AR P150100345A AR P150100345 A ARP150100345 A AR P150100345A AR 099303 A1 AR099303 A1 AR 099303A1
Authority
AR
Argentina
Prior art keywords
aptamer
teranostic
agent
subject
aptamer according
Prior art date
Application number
ARP150100345A
Other languages
English (en)
Spanish (es)
Inventor
Duan Wei
Original Assignee
Univ Deakin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900347A external-priority patent/AU2014900347A0/en
Application filed by Univ Deakin filed Critical Univ Deakin
Publication of AR099303A1 publication Critical patent/AR099303A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
ARP150100345A 2014-02-05 2015-02-06 Construcciones de aptámeros AR099303A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2014900347A AU2014900347A0 (en) 2014-02-05 Aptamer Construct

Publications (1)

Publication Number Publication Date
AR099303A1 true AR099303A1 (es) 2016-07-13

Family

ID=53777070

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100345A AR099303A1 (es) 2014-02-05 2015-02-06 Construcciones de aptámeros

Country Status (10)

Country Link
US (1) US10221420B2 (cg-RX-API-DMAC7.html)
EP (1) EP3102708B1 (cg-RX-API-DMAC7.html)
JP (1) JP6636436B2 (cg-RX-API-DMAC7.html)
CN (1) CN106164293B (cg-RX-API-DMAC7.html)
AR (1) AR099303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015213483B2 (cg-RX-API-DMAC7.html)
CA (1) CA2938776C (cg-RX-API-DMAC7.html)
ES (1) ES2851924T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201606379UA (cg-RX-API-DMAC7.html)
WO (1) WO2015117201A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
US11008575B2 (en) * 2015-07-28 2021-05-18 The University Of North Carolina At Charlotte DNA aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer
WO2017173247A1 (en) * 2016-03-31 2017-10-05 City Of Hope Aptamer compositions and the use thereof
CN105925687A (zh) * 2016-05-15 2016-09-07 陈博 一种用于儿科的肺吸虫病诊断的试剂盒及其诊断方法
EP3332812A1 (en) * 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid-based assembly and use of the assembly in cancer therapy
CN110913910A (zh) * 2017-05-08 2020-03-24 奥曼尼提纳米有限公司 快速进化的生物实体的治疗
CN108866061A (zh) * 2018-06-21 2018-11-23 中山大学附属第五医院 一种识别肝癌细胞的核酸适配体及其筛选方法与用途
KR20210096599A (ko) * 2018-09-28 2021-08-05 어그매니티 나노 엘티디 기능적 압타머의 선택을 위한 방법 및 조성물
CN109439665B (zh) * 2018-12-06 2021-04-02 浙江省肿瘤医院 一种靶向结合cd133蛋白的核酸适配体药物偶联物及其用途
CN109536503B (zh) * 2018-12-06 2021-03-02 浙江省肿瘤医院 一种靶向结合cd133蛋白的核酸适配体及其筛选方法和用途
CN109536505B (zh) * 2018-12-07 2021-11-09 暨南大学 鬼臼毒素的核酸适配体及其应用
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
CN110904112B (zh) * 2019-12-12 2024-04-02 福州市长乐区宝爱冬医学技术有限公司 一种白喉毒素的核酸适配体dt03及其应用
CN110885828B (zh) * 2019-12-12 2024-04-05 方斌 一种白喉毒素的核酸适配体dt01及其应用
CN111505287B (zh) * 2020-05-07 2023-04-07 军事科学院军事医学研究院军事兽医研究所 以乙醛脱氢酶作为信号转导系统检测食源性病原菌的生物传感器及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6127119A (en) 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US6028186A (en) 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6562627B1 (en) 1998-12-23 2003-05-13 Bdc Pharma Llc High throughput method for measurement of physicochemical values
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
AU2003206865B2 (en) 2002-02-08 2007-10-04 D. Collen Research Foundation Vzw A novel target to inhibit angiogenesis
GB0305422D0 (en) 2003-03-10 2003-04-16 Univ Open Detection, monitoring and treatment of cancer
WO2004084950A2 (en) 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
IL179285A (en) 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
EP1795886A4 (en) 2004-08-24 2010-04-07 Fujifilm Corp METHOD FOR CALCULATING THE DISSOCIATION CONSTANT IN SURFACE PLASMON RESONANCE ANALYSIS
EP1789096A4 (en) 2004-09-07 2009-07-08 Archemix Corp APTAMERS FOR THE VON WILLEBRAND FACTOR AND ITS USE AS THERAPEUTICS FOR THROMBOTIC DISEASES
CA2998412C (en) 2004-11-12 2024-01-02 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
CN104623692A (zh) * 2006-03-08 2015-05-20 阿切埃米克斯股份有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
JP2007319153A (ja) 2006-06-02 2007-12-13 Takashi Otsu 核酸リガンドと中和剤との組み合わせ製剤
US20090047295A1 (en) 2007-07-12 2009-02-19 Berry David A Methods and Compositions for Reducing Stemness in Oncogenesis
US20110206614A1 (en) 2007-11-23 2011-08-25 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
US9029163B2 (en) 2010-08-23 2015-05-12 Avia Biosystems, Inc. Method for generation of automated denaturation graphs
MX2015001433A (es) 2012-08-02 2015-09-16 Univ Deakin Aptameros cd133 para deteccion de celulas madre cancerosas.

Also Published As

Publication number Publication date
SG11201606379UA (en) 2016-09-29
EP3102708A4 (en) 2017-10-25
WO2015117201A1 (en) 2015-08-13
AU2015213483B2 (en) 2020-07-02
US20160355820A1 (en) 2016-12-08
CA2938776C (en) 2023-08-22
EP3102708A1 (en) 2016-12-14
US10221420B2 (en) 2019-03-05
CA2938776A1 (en) 2015-08-13
JP6636436B2 (ja) 2020-01-29
CN106164293A (zh) 2016-11-23
ES2851924T3 (es) 2021-09-09
EP3102708B1 (en) 2020-11-18
CN106164293B (zh) 2020-03-27
AU2015213483A1 (en) 2016-08-18
JP2017506074A (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
AR099303A1 (es) Construcciones de aptámeros
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
CL2017000515A1 (es) Cd123 agentes enlazadores y su uso
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
MD4733B1 (ro) Anticorpi anti-TIGIT
UY35682A (es) Anticuerpos anti-activina a y usos de los mismos
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX392416B (es) Métodos y composiciones para terapia celular adoptiva.
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2018002043A (es) ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX381283B (es) Tratamiento de pénfigo.
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
MX2017005325A (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
BR112018003928A2 (pt) métodos para o tratamento de doenças
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
MX374378B (es) Mioinositol y probioticos, y uso de estos.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions

Legal Events

Date Code Title Description
FB Suspension of granting procedure